106 results on '"Morgillo A"'
Search Results
2. Comparison of kink-band structures and specificities of cell wall polysaccharides in modern and ancient flax fibres
3. Revealing degradation mechanisms of archaeological flax textiles through the evolution of fibres’ parietal polymers by synchrotron deep-UV fluorescence
4. Activity of osimeRTInib in non-small-cell lung Cancer with UNcommon epidermal growth factor receptor mutations: retrospective Observational multicenter study (ARTICUNO)
5. Exploring the DNA2-PNA heterotriplex formation in targeting the Bcl-2 gene promoter: A structural insight by physico-chemical and microsecond-scale MD investigation
6. Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis
7. Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario
8. AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer
9. Feasibility of next-generation sequencing in clinical practice: results of a pilot study in the Department of Precision Medicine at the University of Campania ‘Luigi Vanvitelli’
10. Induction of natural killer antibody-dependent cell cytotoxicity and of clinical activity of cetuximab plus avelumab in non-small cell lung cancer
11. Impact of flax fibre kink-bands on local longitudinal mechanical properties and cell wall ultrastructure
12. How I treat malignant pleural mesothelioma
13. Ex vivo lung cancer spheroids resemble treatment response of a patient with NSCLC to chemotherapy and immunotherapy: case report and translational study
14. Three dimensional primary cultures for selecting human breast cancers that are sensitive to the anti-tumor activity of ipatasertib or taselisib in combination with anti-microtubule cytotoxic drugs
15. It is finally time for adjuvant therapy in melanoma
16. Cancer resistance to therapies against the EGFR-RAS-RAF pathway: The role of MEK
17. Results of the safety run-in part of the METAL (METformin in Advanced Lung cancer) study: a multicentre, open-label phase I–II study of metformin with erlotinib in second-line therapy of patients with stage IV non-small-cell lung cancer
18. Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment
19. 168P Effect of sequence treatment of chemotherapy plus radiotherapy activates innate immunity in SCLC
20. Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence
21. Mechanisms of resistance to EGFR-targeted drugs: lung cancer
22. Neutrophil to lymphocyte ratio (NLR) for prediction of distant metastasis-free survival (DMFS) in early breast cancer: a propensity score-matched analysis
23. 73P Effect of combination therapy with atezolizumab plus metformin on peripheral immune cells from NSCLC patients
24. 16P Investigation of c-MYC role in DNA-PK-mediated activation of STING pathway in SCLC
25. 244P DNA-PK inhibition sustains immune activation in SCLC
26. 1810P MYC expression defines distinct transcriptomic landscape and affects response to DNA-damaging therapies in SCLC
27. 1800P Breaking chemo-immunotherapy resistance in SCLC-patient derived tumor with novel DDRi combinations
28. Erratum to ‘Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario’: [ESMO Open Volume 7, Issue 2, April 2022, 100406]
29. Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study
30. A39 - The acquired resistance to the combination of the anti-EGFR cetuximab and the MEK-inhibitor refametinib in KRAS mutated colorectal cancer cell lines depends on PI3K-signalling
31. Erlotinib in cancer treatment
32. Resistance to epidermal growth factor receptor-targeted therapy
33. 1533P Atezolizumab (ATZ) plus carboplatin (Cb) and etoposide (eto) in patients with untreated extensive-stage small cell lung cancer (ES-SCLC): Results from the interim analysis of MAURIS trial
34. 163P Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: Findings from the CAVE-lung trial
35. 1207O Bevacizumab + erlotinib vs erlotinib alone as first-line treatment of pts with EGFR mutated advanced non squamous NSCLC: Final analysis of the multicenter, randomized, phase III BEVERLY trial
36. 1830P Early deaths (ED) upon first-line immunecheckpoint inhibitors (ICI) alone or combined to other non-ICI drugs across solid cancers: A systematic review and meta-analysis
37. 15P A pivotal multicenter translational research project on malignant pleural mesothelioma (MPM): Preliminary results
38. Rethinking treatment for RET-altered lung and thyroid cancers: selpercatinib approval by the EMA
39. 1329P Immune checkpoint inhibitors in advanced NSCLC patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkers in a real world experience
40. 1335P Anti-tumour efficacy of cetuximab plus avelumab in NSCLC through induction of ADCC: Final data from CAVE-lung trial
41. 3O Efficacy of the triple combination of Estrogen Receptor, CDK4/6 and PI3K pathway inhibitors in ex-vivo models of breast cancer
42. 86P - A novel ImmunoScore, based on clinical and blood biomarkers, as prognostic model for immunotherapy in NSCLC
43. 17P - Genomic profiling of non-oncogene-addicted aNSCLC using liquid biopsy. A single institution Italian experience
44. 1909P - Evaluation of antibody-dependent cell cytotoxicity (ADCC) in lung cancer cell lines treated with combined anti-EGFR and anti-PD-L1 therapy
45. 1921P - Proof of concept on the role of ex vivo lung cancer spheroids, cytokines expression and PBMCs profiling in monitoring disease history and response to treatments
46. 66P - Dual inhibition of TGF-β and AXL as a novel treatment for colorectal cancer
47. Early use of steroids affects immune cells and impairs immunotherapy efficacy
48. 1920P - Role of pioglitazone on gene/protein expression profile, bioenergetics and TGFβ/SMAD signaling pathway in NSCLC
49. 1918P - Acquired resistance mechanism of osimertinib targeting EGFR in human lung cancer
50. 1851P - The combination of MEK inhibitor and anti PD-L1: Effects on organoid models from NSCLC biopsies
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.